In addition, activation of the MEK/ERK signaling pathway is involved in PD-L1 modulation in NSCLC cells that harbor either EML4-ALK rearrangement or EGFR mutations 37. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.